# A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

> **NCT01746771** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 44 (actual)

## Conditions studied

- HER-2 Positive Advanced Gastric Cancer

## Interventions

- **DRUG:** HM781-36B(Poziotinib)
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01746771
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2016-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746771, "A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01746771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*